X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (46) 46
trifluridine - pharmacokinetics (35) 35
oncology (32) 32
colorectal cancer (31) 31
index medicus (30) 30
drug combinations (29) 29
trifluridine (29) 29
animals (28) 28
tas-102 (28) 28
male (26) 26
trifluridine - administration & dosage (26) 26
uracil - analogs & derivatives (26) 26
trifluridine - therapeutic use (24) 24
cancer (21) 21
pharmacology & pharmacy (21) 21
colorectal neoplasms - drug therapy (20) 20
female (20) 20
care and treatment (19) 19
metastasis (19) 19
chemotherapy (18) 18
trifluridine - adverse effects (18) 18
uracil - therapeutic use (18) 18
colorectal neoplasms - pathology (16) 16
middle aged (16) 16
trifluorothymidine (16) 16
uracil - adverse effects (16) 16
aged (15) 15
antitumor-activity (14) 14
phase-i (14) 14
solid tumors (14) 14
trifluridine - pharmacology (14) 14
uracil - pharmacokinetics (14) 14
administration, oral (13) 13
trial (13) 13
cancer therapies (12) 12
mice (12) 12
research (12) 12
thymidine phosphorylase (12) 12
5-fluorouracil (11) 11
antineoplastic agents - pharmacokinetics (11) 11
dose-response relationship, drug (11) 11
fluorinated pyrimidines (11) 11
pharmacokinetics (11) 11
tumors (11) 11
uracil - administration & dosage (11) 11
antineoplastic agents - administration & dosage (10) 10
antineoplastic agents - therapeutic use (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
dna (10) 10
neoplasms - drug therapy (10) 10
treatment outcome (10) 10
antineoplastic agents - adverse effects (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
cells (9) 9
disease-free survival (9) 9
medicine & public health (9) 9
metastatic colorectal cancer (9) 9
oncology, experimental (9) 9
pharmacology/toxicology (9) 9
safety and security measures (9) 9
uracil - pharmacology (9) 9
adult (8) 8
drug administration schedule (8) 8
drug therapy (8) 8
thymidine phosphorylase - antagonists & inhibitors (8) 8
antineoplastic agents - pharmacology (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
cancer patients (7) 7
cell line, tumor (7) 7
clinical trials (7) 7
combination antimetabolite (7) 7
cytotoxicity (7) 7
deoxyribonucleic acid--dna (7) 7
mechanism (7) 7
metastatic colorectal-cancer (7) 7
neoplasm metastasis (7) 7
neutropenia (7) 7
patients (7) 7
thymidine - analogs & derivatives (7) 7
thymidine phosphorylase inhibitor (7) 7
thymidylate synthase (7) 7
tipiracil (7) 7
trifluridine/tipiracil (7) 7
5-trifluoromethyl-2'-deoxyuridine (6) 6
analysis (6) 6
cancer research (6) 6
dosage and administration (6) 6
expression (6) 6
inhibition (6) 6
pharmacology (6) 6
rabbits (6) 6
rats (6) 6
regorafenib (6) 6
safety (6) 6
studies (6) 6
thymidine phosphorylase - metabolism (6) 6
trifluridine - blood (6) 6
antimetabolites, antineoplastic - therapeutic use (5) 5
biological availability (5) 5
cell growth-factor (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Science, ISSN 1347-9032, 05/2016, Volume 107, Issue 5, pp. 659 - 665
TAS ‐102, a novel oral antitumor agent, consists of trifluridine and tipiracil hydrochloride (molar ratio, 1:0.5). We investigated the effects of food on... 
pharmacokinetics | Effect of food | 102 | tipiracil hydrochloride | trifluridine | TAS | TAS-102 | Tipiracil hydrochloride | Trifluridine | Pharmacokinetics | VIVO | 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE | ANTITUMOR-ACTIVITY | CANCER | TRIAL | ONCOLOGY | FLUORINATED PYRIMIDINES | DEOXYRIBONUCLEIC ACID | THYMIDINE PHOSPHORYLASE | Neoplasms - metabolism | Thymine - pharmacokinetics | Nausea - chemically induced | Area Under Curve | Humans | Middle Aged | Pyrrolidines - adverse effects | Biological Availability | Male | Antineoplastic Agents - therapeutic use | Trifluridine - pharmacokinetics | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Uracil - pharmacology | Antineoplastic Agents - adverse effects | Leukopenia - chemically induced | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Thymine - pharmacology | Neutropenia - chemically induced | Trifluridine - pharmacology | Fasting | Thymine - therapeutic use | Thymine - adverse effects | Pyrrolidines - pharmacokinetics | Food-Drug Interactions | Japan | Anemia - chemically induced | Uracil - therapeutic use | Neoplasms - drug therapy | Cross-Over Studies | Trifluridine - therapeutic use | Asian Continental Ancestry Group | Uracil - adverse effects | Trifluridine - adverse effects | Aged | Neoplasms - pathology | Uracil - pharmacokinetics | Drug Combinations | Uracil - analogs & derivatives | Drugs | Complications and side effects | Care and treatment | Safety and security measures | Analysis | Colorectal cancer | Prostate cancer | Tumors | Food | Lung cancer | Metastasis | Cancer therapies | Thymus | Consent | Safety | Meals | Drug dosages | Neutropenia | Leukopenia | Hematology | Research funding | Neutrophils | Nausea | Leukocytes (neutrophilic) | Bioavailability | Patients | Studies | Rectum | Breast | Clinical medicine | Solid tumors | Prostate | Pharmaceuticals | TAS‐102 | Original
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2017, Volume 35, Issue 2, pp. 189 - 197
Background Trifluridine, a thymidine-based chemotherapeutic, has limited bioavailability after clinical administration as it is rapidly degraded via thymidine... 
Medicine & Public Health | Trifluridine/tipiracil | Advanced solid tumors | Oncology | Trifluridine | Pharmacology/Toxicology | Pharmacokinetics | Fluoropyrimidine | TRIAL | SOLID TUMORS | ONCOLOGY | PHARMACOLOGY & PHARMACY | METASTATIC COLORECTAL-CANCER | Neoplasms - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Thymine - pharmacokinetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Trifluridine - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Trifluridine - pharmacokinetics | Pyrrolidines - therapeutic use | Drug Interactions | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Thymine - administration & dosage | Thymine - therapeutic use | Thymine - adverse effects | Pyrrolidines - pharmacokinetics | Treatment Outcome | Neoplasms - drug therapy | Trifluridine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Trifluridine - adverse effects | Aged | Care and treatment | Analysis | Dosage and administration | Drug therapy | Tumors | Studies | Clinical trials | Medical research | Pharmacology | Cancer therapies | tipiracil | Phase I Studies
Journal Article
Cancer, ISSN 0008-543X, 09/2006, Volume 107, Issue 6, pp. 1383 - 1390
Journal Article
Journal Article
International Journal of Oncology, ISSN 1019-6439, 6/2015, Volume 46, Issue 6, pp. 2327 - 2334
Journal Article
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 197 - 206
Trifluridine (FTD) is an active cytotoxic component of the metastatic colorectal cancer (mCRC) drug TAS-102, and thymidine phosphorylase inhibitor (TPI)... 
TAS-102 | Trifluridine | Thymidine phosphorylase inhibitor | Transporter | Metastatic colorectal cancer | THYMIDINE KINASE | METFORMIN | CELLS | SOLID TUMORS | TRIFLUOROTHYMIDINE | NUCLEOSIDE TRANSPORTERS | 5-FLUOROURACIL | ONCOLOGY | OCT2 | RESISTANCE | PHASE-I | Predictive Value of Tests | Colorectal Neoplasms - genetics | Humans | Organic Cation Transporter 2 - metabolism | Male | Antineoplastic Agents - therapeutic use | Trifluridine - pharmacokinetics | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Pharmacogenomic Variants | Female | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Pharmacogenetics | Organic Cation Transport Proteins - metabolism | Gene Frequency | Japan | Equilibrative Nucleoside Transporter 1 - genetics | Uracil - therapeutic use | Genotype | Treatment Outcome | Equilibrative Nucleoside Transporter 1 - metabolism | California | Pharmacogenomic Testing | Trifluridine - therapeutic use | Disease-Free Survival | Phenotype | Uracil - adverse effects | Trifluridine - adverse effects | Italy | Polymorphism, Single Nucleotide | Colorectal Neoplasms - pathology | Organic Cation Transport Proteins - genetics | Uracil - pharmacokinetics | Organic Cation Transporter 2 - genetics | Drug Combinations | Uracil - analogs & derivatives | Cancer patients | Genes | Colorectal cancer | Nucleosides | Physiological aspects | Genetic research | Genetic aspects | Single nucleotide polymorphisms | Metastasis
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 62, pp. 46 - 53
Journal Article
Drugs, ISSN 0012-6667, 7/2018, Volume 78, Issue 11, pp. 1133 - 1144
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2007, Volume 96, Issue 1, pp. 61 - 66
The Hollow Fibre Assay (HFA) is usually applied as an early in vivo model for anti-cancer drug screening, but is potentially an excellent model for short-term... 
Fluoropyrimidines | TAS-102 | In vivo pharmacodynamics | Colon cancer | Antimetabolites | Hollow fibre assay | VITRO | CHEMOSENSITIVITY | MECHANISM | colon cancer | THYMIDYLATE SYNTHASE | SENSITIVITY | ANTITUMOR-ACTIVITY | HUMAN-TUMOR XENOGRAFTS | ONCOLOGY | COMBINATION ANTIMETABOLITE | fluoropyrimidines | antimetabolites | hollow fibre assay | in vivo pharmacodynamics | THYMIDINE PHOSPHORYLASE INHIBITOR | Apoptosis - drug effects | Capecitabine | Colonic Neoplasms - drug therapy | Humans | Floxuridine - pharmacokinetics | Trifluridine - pharmacokinetics | Fluorouracil - therapeutic use | Deoxycytidine - pharmacokinetics | Deoxycytidine - therapeutic use | Flow Cytometry | Enzyme Inhibitors - pharmacokinetics | Sensitivity and Specificity | Floxuridine - therapeutic use | Tumor Cells, Cultured | Thymidine Phosphorylase - antagonists & inhibitors | Fluorouracil - analogs & derivatives | Administration, Oral | Uracil - therapeutic use | Treatment Outcome | Xenograft Model Antitumor Assays - methods | Enzyme Inhibitors - therapeutic use | Drug Synergism | Trifluridine - therapeutic use | Animals | Cell Line, Tumor | Mice | Mice, Inbred BALB C | Cell Cycle - drug effects | Fluorouracil - pharmacokinetics | Uracil - pharmacokinetics | Deoxycytidine - analogs & derivatives | Drug Combinations | Uracil - analogs & derivatives | Translational Therapeutics
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2008, Volume 26, Issue 5, pp. 445 - 454
Journal Article
Journal Article